Evaluating the Relevance of Non-invasive Measurement of Protein Synthesis by Gallium-68-DOTA-puromycin PET/MRI for Imaging of Mycobacterial Infection - a Preclinical Report

0579002 - ÚJF 2024 RIV US eng A - Abstrakt
Kleynhans, J. - Eigner, Sebastian - Sathekge, M. M. - Ebenhan, T.
Evaluating the Relevance of Non-invasive Measurement of Protein Synthesis by Gallium-68-DOTA-puromycin PET/MRI for Imaging of Mycobacterial Infection - a Preclinical Report.
European Journal of Nuclear Medicine and Molecular Imaging. Springer. Roč. 50, Supplement 1 (2023), S464-S464. ISSN 1619-7070. E-ISSN 1619-7089.
[Annual Congress of the European Association of Nuclear Medicine (ENAM'23). 09.09.2023-13.09.2023, Vienna]
Institucionální podpora: RVO:61389005
Klíčová slova: radiology * 68-Ga-DOTA * PET/MRI
Obor OECD: Radiology, nuclear medicine and medical imaging
https://doi.org/10.1007/s00259-023-06333-x

Puromycin is a relevant scafold for the development of a radiopharmaceutical that will allow the quantifcation of protein synthesis non-invasively through nuclear based imaging techniques. A signifcant clinical application of radiolabeled puromycin depends on the visualization of mycobacterial protein synthesis for future clinical investigations of tuberculous lesions. To date, no systematic characterization of a puromycin-based radiopharmaceuticals as potential in vivo infection imaging agents has been reported. Therefore, this study will address selectivity, sensitivity, and accuracy of [68Ga]Ga-DOTA-puromycin-micro-positron emission tomography combined with magnetic resonance imaging (microPET/MRI) imaging to determine the role and value of this technique to detect mycobacterial infection in vivo.
Trvalý link: https://hdl.handle.net/11104/0347881